These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 15554743)

  • 1. Can we ensure the safe use of known human teratogens? Introduction of generic isotretinoin in the US as an example.
    Honein MA; Moore CA; Erickson JD
    Drug Saf; 2004; 27(14):1069-80. PubMed ID: 15554743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparative review of the isotretinoin pregnancy risk management programs across four continents.
    Kovitwanichkanont T; Driscoll T
    Int J Dermatol; 2018 Sep; 57(9):1035-1046. PubMed ID: 29508918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A survey of pregnant women using isotretinoin.
    Robertson J; Polifka JE; Avner M; Chambers C; Delevan G; Koren G; Lavigne SV; Martinez LP; Miller RK; Carey JC
    Birth Defects Res A Clin Mol Teratol; 2005 Nov; 73(11):881-7. PubMed ID: 16228976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessing the availability of the teratogenic drug isotretinoin outside the pregnancy prevention programme: a survey of e-pharmacies.
    Lagan BM; Dolk H; White B; Uges DR; Sinclair M
    Pharmacoepidemiol Drug Saf; 2014 Apr; 23(4):411-8. PubMed ID: 24493556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trends in adherence to a revised risk management program designed to decrease or eliminate isotretinoin-exposed pregnancies: evaluation of the accutane SMART program.
    Brinker A; Kornegay C; Nourjah P
    Arch Dermatol; 2005 May; 141(5):563-9. PubMed ID: 15897377
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isotretinoin exposure and pregnancy outcome: an observational study of the Berlin Institute for Clinical Teratology and Drug Risk Assessment in Pregnancy.
    Schaefer C; Meister R; Weber-Schoendorfer C
    Arch Gynecol Obstet; 2010 Feb; 281(2):221-7. PubMed ID: 19444462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fetal exposure to isotretinoin-an international problem.
    Garcia-Bournissen F; Tsur L; Goldstein LH; Staroselsky A; Avner M; Asrar F; Berkovitch M; Straface G; Koren G; De Santis M
    Reprod Toxicol; 2008 Jan; 25(1):124-8. PubMed ID: 18077132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Isotretinoin (Roaccutane) in women of childbearing age: failure of following prescription guidelines].
    Autret E; Radal M; Jonville-Béra AP; Goehrs JM
    Ann Dermatol Venereol; 1997; 124(8):518-22. PubMed ID: 9740842
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An opportunity for improvement: iPLEDGE policy changes during the coronavirus pandemic.
    Pathoulas JT; Farah RS; Fiessinger L; Mansh M
    Dermatol Ther; 2020 Nov; 33(6):e14411. PubMed ID: 33052629
    [No Abstract]   [Full Text] [Related]  

  • 10. Can we ensure the safe use of known human teratogens?: The iPLEDGE test case.
    Honein MA; Lindstrom JA; Kweder SL
    Drug Saf; 2007; 30(1):5-15. PubMed ID: 17194167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. "Be smart, be safe, be sure". The revised Pregnancy Prevention Program for women on isotretinoin.
    Perlman SE; Leach EE; Dominguez L; Ruszkowski AM; Rudy SJ
    J Reprod Med; 2001 Feb; 46(2 Suppl):179-85. PubMed ID: 11255826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Compliance with pregnancy prevention programmes of isotretinoin in Europe: a systematic review.
    Crijns HJ; Straus SM; Gispen-de Wied C; de Jong-van den Berg LT
    Br J Dermatol; 2011 Feb; 164(2):238-44. PubMed ID: 20716214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral isotretinoin and pregnancy prevention programmes.
    Thiboutot D; Gollnick H; Bettoli V; Dréno B; Kang S; Leyden JJ; Shalita A; Torres V;
    Br J Dermatol; 2012 Feb; 166(2):466-7; author reply 467-8. PubMed ID: 21985025
    [No Abstract]   [Full Text] [Related]  

  • 14. Isotretinoin: Still the cause of anxiety for teratogenicity.
    Altıntaş Aykan D; Ergün Y
    Dermatol Ther; 2020 Jan; 33(1):e13192. PubMed ID: 31837244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Isotretinoin: compliance with recommendations in childbearing women].
    Bensouda-Grimaldi L; Jonville-Béra AP; Mouret E; Elefant E; Dhellot H; Delmas C; Gouin T; Coste P; Autret-Leca E;
    Ann Dermatol Venereol; 2005 May; 132(5):415-23. PubMed ID: 15988352
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Accutane-exposed pregnancies--California, 1999.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2000 Jan; 49(2):28-31. PubMed ID: 10680601
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implementation of the harmonized EU isotretinoin Pregnancy Prevention Programme: a questionnaire survey among European regulatory agencies.
    Crijns I; Straus S; Luteijn M; Gispen-de Wied C; Raine J; de Jong-van den Berg L
    Drug Saf; 2012 Jan; 35(1):27-32. PubMed ID: 22050373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concomitant use of isotretinoin and contraceptives before and after iPledge in the United States.
    Pinheiro SP; Kang EM; Kim CY; Governale LA; Zhou EH; Hammad TA
    Pharmacoepidemiol Drug Saf; 2013 Dec; 22(12):1251-7. PubMed ID: 23913625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prenatal exposure to teratogenic medications in the era of Risk Evaluation and Mitigation Strategies.
    Sarayani A; Albogami Y; Thai TN; Smolinski NE; Patel P; Wang Y; Nduaguba S; Rasmussen SA; Winterstein AG
    Am J Obstet Gynecol; 2022 Aug; 227(2):263.e1-263.e38. PubMed ID: 35032444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generic isotretinoin: a new risk for unborn children.
    Koren G; Avner M; Shear N
    CMAJ; 2004 May; 170(10):1567-8. PubMed ID: 15136551
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.